Sugi Predict

Sugi Predict / Compounds / SCHEMBL2115989

SCHEMBL2115989

SCHEMBL2115989

N#Cc1cncc(C(=O)O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 6/20 0.52
▸ ALDH1A1 P00352 4/20 0.52
▸ KDM4E B2RXH2 3/20 0.52
▸ MEN1 O00255 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ POLB P06746 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ DDO Q99489 1/20 0.52
▸ NPC1 O15118 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ SLC22A12 Q96S37 1/20 0.47
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ MKNK1 Q9BUB5 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ LRRK2 Q5S007 1/20 0.40
▸ XDH P47989 1/20 0.40
▸ MAP4K4 O95819 1/20 0.40
▸ APP P05067 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30281262 1.00 HCAR2 (0.52) HCAR2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL9296654 0.82 CYP11B2 (0.50) HCAR2ALDH1A1MKNK1MKNK2LRRK2
SCHEMBL3821120 0.82 CYP11B2 (0.50) MKNK1MKNK2LRRK2XDH
SCHEMBL30503762 0.82 LRRK2 (0.38) HCAR2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL8922148 0.82 HCAR2 (0.53) HCAR2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL31064091 0.80 HCAR2 (0.52) HCAR2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL20500079 0.80 HCAR2 (0.52) HCAR2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL9446844 0.79 CYP11B2 (0.39) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL25405895 0.79 GPR35 (0.37) HCAR2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL25406968 0.79 ALDH1A1 (0.37) HCAR2ALDH1A1NPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117832605-B Composite solid electrolyte and all-solid-state lithium battery cell 东莞市红树林新能源有限公司 2024-06-11 — — CN claimed
CN-117832605-A Composite solid electrolyte and all-solid-state lithium battery cell 东莞市红树林新能源有限公司 2024-04-05 — — CN claimed
US-20050171346-A1 Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation AVENTIS PHARMA S.A. (FR) 2005-08-04 — — US claimed
EP-4737443-A1 SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Tanabe Pharma Corporation (JP) 2026-05-06 — — EP disclosed
EP-4720060-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2026-04-08 — — EP disclosed
US-20260062387-A1 SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME MITSUBISHI TANABE PHARMA CORPORATION (JP) 2026-03-05 — — US disclosed
US-20250375526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-12-11 — — US disclosed
EP-4620470-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-24 — — EP disclosed
EP-4615455-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-17 — — EP disclosed
EP-4143195-B1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2025-05-21 — — EP disclosed
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-17 — — US disclosed
WO-2011088181-A9 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-31 — — WO disclosed
WO-2011088181-A9 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-31 — — WO disclosed
EP-2533783-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals, Inc. (US) 2012-12-19 — — EP disclosed
US-20120094993-A1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-04-19 — — US disclosed
WO-2012049190-A1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-04-19 — — WO disclosed
WO-2011088181-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 — — WO disclosed
WO-2011088181-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 — — WO disclosed
US-7034022-B2 Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation AVENTIS PHARMA S. A. (FR) 2006-04-25 — — US disclosed
US-20050171346-A1 Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation AVENTIS PHARMA S.A. (FR) 2005-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062387-A1 SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME SIK1, SIK3, SIK2 HCAR2 1933/4885ALDH1A1 3731/4885KDM4E 1508/4885
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HCAR2 983/4885ALDH1A1 2776/4885KDM4E 190/4885
US-20250375526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HCAR2 983/4885ALDH1A1 2776/4885KDM4E 190/4885
US-20050171346-A1 Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation HEXD, CDK5, CHUK HCAR2 27/4885ALDH1A1 454/4885KDM4E 2612/4885
US-20120094993-A1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES APOB, CETP, NPC1L1 HCAR2 425/4885ALDH1A1 1510/4885KDM4E 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.